Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Glimepiride+metformin (Amaryl M®) - HOE4900
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 167
- Registration Number
- NCT01699932
- Locations
- 🇺🇦
Investigational Site Number 804002, Vinnytsya, Ukraine
🇱🇧Investigational Site Number 422-002, Beirut, Lebanon
🇱🇧Investigational Site Number 422-001, Hazmieh, Lebanon
Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine new formulation (HOE901)Drug: Insulin glargine (HOE901) (Lantus)
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 243
- Registration Number
- NCT01689129
- Locations
- 🇯🇵
Investigational Site Number 392117, Izumisano-Shi, Japan
🇯🇵Investigational Site Number 392104, Shinjuku-Ku, Japan
🇯🇵Investigational Site Number 392116, Osaka-Shi, Japan
Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine (HOE901)Drug: Insulin glargine new formulation (HOE901)
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT01689142
- Locations
- 🇯🇵
Investigational Site Number 392226, Amagasaki-Shi, Japan
🇯🇵Investigational Site Number 392223, Izumisano-Shi, Japan
🇯🇵Investigational Site Number 392209, Chuo-Ku, Japan
Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2015-02-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT01690403
- Locations
- 🇺🇸
Investigational Site Number 840001, Buffalo, New York, United States
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: HOE901-U300 (Insulin glargine new formulation)
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 549
- Registration Number
- NCT01683266
- Locations
- 🇨🇿
Investigational Site Number 203103, Praha 8, Czech Republic
🇨🇦Investigational Site Number 124109, Montreal, Canada
🇪🇪Investigational Site Number 233104, Pärnu, Estonia
Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: insulin glargine (HOE901)Drug: insulin glargine- new formulation (HOE901)
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT01676233
- Locations
- 🇯🇵
Investigational Site Number 392001, Kumamoto-Shi, Japan
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: HOE901-U300 (new formulation of insulin glargine)
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 878
- Registration Number
- NCT01676220
- Locations
- 🇺🇸
Investigational Site Number 840297, Torrance, California, United States
🇺🇸Investigational Site Number 840232, Overland Park, Kansas, United States
🇺🇸Investigational Site Number 840248, Hollywood, Florida, United States
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 75
- Registration Number
- NCT01673737
- Locations
- 🇺🇸
Investigational Site Number 840001, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840002, Houston, Texas, United States
🇺🇸Investigational Site Number 840101, Boston, Massachusetts, United States
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT01670734
- Locations
- 🇫🇷
Investigational Site Number 250001, Rennes, France
🇲🇩Investigational Site Number 498001, Chisinau, Moldova, Republic of
Colorectal Cancer Metastatic
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 175
- Registration Number
- NCT01670721
- Locations
- 🇫🇷
Administrative office, Paris, France